Sanofi’s Venglustat shows breakthrough results in rare neurological Gaucher disease

Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs

Richter’s FYLREVY to transform menopause care in Europe?

The recommendation covers FYLREVY 14.2 mg and 18.9 mg for non-hysterectomised postmenopausal women experiencing oestrogen deficiency symptoms at least 12 months after their last menses

Siemens Healthineers launches €10 million R&D hub in Swords, Ireland

The facility is dedicated to breakthrough innovations in laboratory instruments that detect infectious diseases, cancer, and blood disorders

Arctic Vision expands global reach with acquisition of MDCO Technology’s ophthalmic device business

Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy

N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway

Pfizer’s monthly obesity drug shows breakthrough weight loss in Phase 2b trial

The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated

Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research

The new service delivers end-to-end support, managing every stage of an epigenomics project

SPARC announces receipt of priority review voucher associated with Sezaby approval

A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases

Wanbury achieves first sales invoicing and commercial shipment milestone

This achievement validates global demand and catapults Wanbury into high-growth acceleration

Zydus Wellness net sales up by 113.7% in Q3 FY26

Glucon-D maintained its leadership position with a 59% MAT market share